Akihito Tsubota
Overview
Explore the profile of Akihito Tsubota including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
195
Citations
1411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ueda K, Oikawa T, Yamada K, Tsubota A, Saeki C, Katagiri K, et al.
Biochem Biophys Res Commun
. 2025 Feb;
751:151431.
PMID: 39908908
Protein kinase C delta (PKCδ) is a leaderless protein generally localized in the cytoplasm and nucleus; however, its extracellular unconventional protein secretion occurs exclusively in hepatocellular carcinoma (HCC) cells (but...
2.
Niwa T, Saeki C, Saito M, Oikawa T, Kamioka H, Kanai T, et al.
Sci Rep
. 2025 Jan;
15(1):186.
PMID: 39747234
Frailty and fractures are closely associated with adverse clinical outcomes. This retrospective study investigated the prognostic impact of frailty, prevalent fractures, and the coexistence of both in patients with cirrhosis....
3.
Tamura Y, Saeki C, Kanai T, Kiryu S, Nakano M, Oikawa T, et al.
J Gastroenterol Hepatol
. 2024 Nov;
40(1):274-281.
PMID: 39511932
Background And Aim: Sarcopenia and osteoporosis adversely impact the clinical outcomes of patients with chronic liver disease (CLD). The Japan Society of Hepatology (JSH) sarcopenia criteria utilize bioelectrical impedance analysis...
4.
Kamioka H, Saeki C, Oikawa T, Kinoshita A, Kanai T, Ueda K, et al.
BMC Gastroenterol
. 2024 Oct;
24(1):376.
PMID: 39448932
Background: Patients with chronic liver disease (CLD) frequently suffer from malnutrition and bone diseases, both of which heighten the risk of poor clinical outcomes. This study investigated the relationship between...
5.
Arai T, Atsukawa M, Tsubota A, Oikawa T, Tada T, Matsuura K, et al.
Diabetes Obes Metab
. 2024 Sep;
26(11):4958-4965.
PMID: 39223865
Aims: To evaluate the efficacy and safety of oral semaglutide for type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Materials And Methods: This was...
6.
Toyoda H, Atsukawa M, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, et al.
Gastro Hep Adv
. 2024 Aug;
1(4):508-515.
PMID: 39132067
Backgrounds And Aims: Cirrhosis and hepatocellular carcinoma (HCC) are potentially fatal complications of chronic hepatitis C virus (HCV) infection. We investigated how compensated cirrhosis and a history of curatively treated...
7.
Oikawa T, Yamada K, Tsubota A, Saeki C, Tago N, Nakagawa C, et al.
Gastro Hep Adv
. 2024 Aug;
2(1):83-95.
PMID: 39130149
Backgrounds And Aims: Hepatocellular carcinoma (HCC) is the most common cancer with a poor prognosis. Identification of an alternative biomarker that can detect early-stage and conventional tumor marker-negative HCC is...
8.
Atsukawa M, Tsubota A, Kondo C, Toyoda H, Takaguchi K, Nakamuta M, et al.
J Gastroenterol
. 2024 May;
59(8):709-718.
PMID: 38727822
Background: This study aimed to clarify the morphological changes in esophageal varices after achieving sustained virological response (SVR) with direct-acting antivirals (DAAs) in patients with cirrhosis. Methods: A total of...
9.
Itokawa N, Atsukawa M, Tsubota A, Ishikawa T, Toyoda H, Takaguchi K, et al.
Hepatol Res
. 2024 Apr;
54(11):993-1003.
PMID: 38685853
Aim: An association between hepatitis B core-related antigen (HBcrAg) kinetics and hepatocarcinogenesis during nucleoside (t)id analog (NA) treatment has recently been reported. HBcrAg kinetics and factors associated with HBcrAg response...
10.
Ono H, Atsukawa M, Tsubota A, Arai T, Suzuki K, Higashi T, et al.
JGH Open
. 2024 Apr;
8(4):e13057.
PMID: 38572327
Background And Aim: This study aimed to clarify the efficacy and safety of 48-week pemafibrate treatment in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) complicated by dyslipidemia. Methods: A...